Global Mental Health Summit

• 11:30 AM–12:30 PM: “Technology & Innovation: AI, Social Responsibility & the American Ibogaine Initiative” This session will connect Andrew Romero’s AI infrastructure with the policy and clinical mission of the American Ibogaine Initiative, supported by MyungHi S. Lee and KRFI. Key discussion areas include:

• These AI platforms demonstrate strong performance across diverse domains, including:

  • AI-enhanced investment frameworks for Ibogaine deployment

  • Public–private partnership models supporting mental health reform

  • Responsible funding strategies for bipartisan state-level Ibogaine bills

  • Ethical scaling, oversight, and corporate social responsibility

  • Building national infrastructure for Ibogaine-based mental health intervention

Together, the speakers outline how AI, biotechnology, and responsible investment can accelerate safe, equitable, and evidence-based Ibogaine access for veterans, Indigenous communities, and Americans facing mental health and addiction crises. Andrew Romero leads the development of high-reliability AI at InferenceFrame, where he designs and deploys advanced structured reasoning systems that strengthen decision-making in high-stakes environments. His work centers on Neuro-Symbolic (NeSy) approaches that integrate mathematical and logical reasoning, enabling AI systems to perform with greater precision and significantly reduced data requirements. InferenceFrame’s technology has been used to generate actionable insights for companies, investment funds, and research organizations, supported by strategic institutional funding. The company has also established cost-sensitive licensing agreements, allowing scalable access to its reasoning systems. These AI platforms demonstrate strong performance across diverse domains, including:

·                 

                   Financial markets & capital allocation

·                  Robotics & autonomous systems

·                  Mathematical and scientific discovery

·                  Risk assessment and high-stakes decision support

​

Andrew has also developed a suite of AI-driven investment banking tools, supporting capital structuring, due diligence, and near-automated deal execution. These technologies help reduce operational bottlenecks and increase accuracy in financial decision-making. InferenceFrame’s systems are adopted through partnerships with major FINRA-member firms, including GT Securities, where Andrew serves as Director.

​

• 12:30 - 1:30 PM: ​ Moderated by Paul Sladkus, This session features Guest Speaker Dr. Ken Alper, M.D. (TBA) and introduces a collaborative framework for an Ibogaine Clinical R&D Alliance focused on FDA/MHRA/EMEA/ANVISA–registered clinical trial reporting and mechanism-of-action research.  The discussion highlights the KRFI Questors open-source clinical data platform, designed to address a persistent challenge in psychiatric research: fewer than 10% of clinical studies adequately assess blinding integrity, even though blinding is treated as a foundational element of clinical trial design. Without transparent, shared, and high-quality data, the field faces limitations in cost efficiency, reproducibility, and the ability to resolve the consequences of unblinding on data interpretation—issues that are especially critical for advancing Ibogaine and psychedelic-based mental health therapeutics.​

• Establishing the Independent Ibogaine & Psychedelic Clinical Evidence Assessment Working Group (I&PCEA-WG). As clinical programs grow in complexity—particularly those integrating psychotherapy with pharmacological interventions—KRFI is convening an Independent Ibogaine and Psychedelic Evidence Assessment Working Group (I&PCEA-WG). This initiative brings together experts across disciplines to explore “evidential pluralism” as a complementary framework to traditional evidence assessment models in psychiatry and medicine.  The goal is to develop more adaptive, realistic standards for evaluating therapeutic outcomes in Ibogaine and psychedelic science—standards that acknowledge multiple forms of evidence and the unique properties of consciousness-altering treatments.       Evidential Pluralism & New Directions in Clinical Evidence.  The presentation also reflects on a recent announcement from Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, which is developing an evidentiary framework better aligned with the complexities of emerging mental health treatments. As noted in contemporary philosophy of science, no single research methodology is infallible, and exclusive reliance on randomized controlled trials may unintentionally restrict patient access to promising therapies.  Collaborative mechanisms for advancing Ibogaine as an evidence-based treatment for mental health and addiction.  This presentation sets the stage for a next-generation clinical research framework—one capable of supporting Ibogaine and psychedelic sciences as they enter mainstream medical, regulatory, and global health systems. A more balanced approach—one that incorporates rigor while allowing methodological flexibility—is essential. This includes distinguishing between risk of bias and actual bias, and evaluating clinical evidence in a way that is both scientifically sound and responsive to the realities of psychedelic-assisted therapies.

  • A Path Forward for Ibogaine Science Together, the speakers will outline a pathway toward:

  • ·       More robust and transparent clinical trial reporting across regulatory jurisdictions

  • ·       Improved strategies for evaluating blinding integrity and treatment fidelity

  • ·       Integration of evidential pluralism to support innovative, safe, and equitable access

  • ​

  • 1:30 - 2:30 PM  Moderated by MyungHi S. Lee, this session opens with an introduction by W. Bryan Hubbard, presenting Americans for Ibogaine, followed by an update on the State of the National Ibogaine Consortium (TBA) and its role in a Public–Private Sector Partnership in Ibogaine Clinical Research.  The session will cover the New York State Ibogaine Research Bill Action Plan for January 2026, including:

  • • Upcoming NYS Senate hearings featuring Ibogaine testimonials

      • Coordinated state-level action plans in NYS, Texas, Arizona, Ohio, and Colorado

      • Responses from state authorities across the United States

      • Policy and Mental Health Strategy: The discussion will focus on mental health policy initiatives in New York State, exploring the allocation of $12 billion USD toward mental health and addiction programs. Special emphasis will be placed on the NYS Ibogaine Research Bill, led by Bipartisan Senate sponsors Natalie Rodriguez (D) and Jacob Ashby (R).

    • Key policy priorities include:

      • Health equity in addiction treatment for opioid and substance use disorders (OUD/SUD)

      • Veteran-focused programs addressing traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD)

      • Integration of evidence-based psychedelic therapies, such as Ibogaine, into mainstream treatment pathways

    • Goals and Outcomes: This session aims to:

      • Provide a comprehensive update on national and state Ibogaine initiatives

      • Highlight the coordination between public and private sectors in clinical research

      • Present strategies for advancing legislation, funding, and mental health equity programs

      • Identify opportunities for evidence-based implementation of Ibogaine in OUD/SUD and veteran care

    • This presentation positions Ibogaine within the broader framework of national mental health policy, bipartisan legislative action, and equitable access for vulnerable populations.